<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27556316</article-id><article-id pub-id-type="pmc">5062719</article-id><article-id pub-id-type="doi">10.5935/1678-9741.20160034</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Articles</subject></subj-group></article-categories><title-group><article-title>Mitral Valve Prolapse in Pregnancy</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Yuan</surname><given-names>Shi-Min</given-names></name><degrees>MMed, PhD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Yan</surname><given-names>Song-Li</given-names></name><degrees>MMed</degrees><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="c1"/></contrib><aff id="aff1"><label>1</label>The First Hospital of Putian, Teaching Hospital,
Fujian Medical University, Fujian Province, China.</aff></contrib-group><author-notes><corresp id="c1">Correspondence Address: Song-Li Yan, Longdejing Street, 389 -
Chengxiang District, Putian, Fujian Province, People's Republic of China. -mail:
<email>yansl2006@163.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Mar-Apr</season><year>2016</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Mar-Apr</season><year>2016</year></pub-date><volume>31</volume><issue>2</issue><fpage>158</fpage><lpage>162</lpage><history><date date-type="received"><day>27</day><month>10</month><year>2015</year></date><date date-type="accepted"><day>25</day><month>4</month><year>2016</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><p>Mitral valve prolapse is a benign condition. Mitral regurgitation is only
complicated in patients with severe mitral valve prolapse. Women with mitral
valve prolapse in the absence of other cardiovascular disorders tolerate
pregnancy well and do not develop remarkable cardiac complications.
Nevertheless, serious complications of mitral valve prolapse, including
arrhythmia, infective endocarditis and cerebral ischemic events, can be present
in pregnancy. Debates remain with regard to the use of prophylactic antibiotics
and &#x003b2;-blockers in the pregnant women with mitral valve prolapse. The
prognosis of the pregnant patients might be closely related to the pathological
and (or) functional changes of the mitral valve. Non-myxomatous mitral valve
prolapse poses no or little obstetric risks in terms of pregnancy, labor and
neonatal complications; whereas myxomatous mitral valve prolapse is a major
etiology of valvular heart disease in women of childbearing age. In the pregnant
patients with mitral valve prolapse progressing into major complications,
surgical interventions are considered. Medicinal treatment of such patients with
&#x003b2;-blockers should be a concern for the fetal safety.</p></abstract><kwd-group><kwd>Mitral Valve Insufficiency</kwd><kwd>Mitral Valve Prolapse</kwd><kwd>Pregnancy</kwd></kwd-group></article-meta></front><body><table-wrap id="t1" orientation="portrait" position="anchor"><table frame="hsides" rules="groups" style="background-color:#e6e7e8"><colgroup span="1"><col width="10%" span="1"/><col width="90%" span="1"/></colgroup><thead><tr><th colspan="2" align="left" rowspan="1">Abbreviations, acronyms &#x00026; symbols</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">MR</td><td rowspan="1" colspan="1">= Mitral regurgitation</td></tr><tr><td rowspan="1" colspan="1">MVP</td><td rowspan="1" colspan="1">= Mitral valve prolapse</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>Mitral valve prolapse (MVP) is defined as a prolapse of one or both mitral valve
leaflets at least 2 mm beyond the long axis annular plane with or without mitral
thickening<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>. MVP is
characterized by elongated chordae tendineae and redundant valve leaflets, which
prolapse into the left atrial cavity as the ventricle contacts. The prolapse may or
may not result in mitral regurgitation (MR)<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup>. It is uncommon that the patients are complicated with
severe sequelae, the most frequent of which are severe MR that usually warrants a
surgical correction<sup>[<xref rid="r3" ref-type="bibr">3</xref>]</sup>. MVP may be
due to a primary connective tissue disease involving the mitral valve leaflets, the
subvalvular apparatus, or the mitral annulus, or secondary to mitral valve apparatus
abnomalities. Primary or idiopathic MVP is usually associated with myxomatous,
redundant valve leaflets and progressive annular dilation. In contrast, patients
with secondary MVP have thin leaflets, which prolapse slightly into the left atrium
during systole as a result of mismatch of the anatomical relationship between the
mitral valve apparatus and left ventricle. Hence, secondary MVP may be seen in
secundum atrial septal defects, infective endocarditis, rheumatic mitral stenosis
and calcified mitral annulus<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup>.
The reason of the mucopolysaccharide accumulation predilection in the mitral valve
remains uncertain. MVP was also regarded as an autosomal dominant cardiac
abnormality with age and sex dependent expression<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup>. Nevertheless, it is believed that MVP is a result
of progressive myxomatous valve changes and it may bring about chordal rupture in
some patients<sup>[<xref rid="r6" ref-type="bibr">6</xref>]</sup>. The progression
of MVP into severe MR usually occur after the age of 50 years<sup>[<xref rid="r3" ref-type="bibr">3</xref>]</sup>; whereas younger patients may have
good exercise tolerance, and would not show any circulatory deterioration<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup>.</p><p>Cardiac problems in pregnancy have been a contemporary important topic of
concern<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup>. The incidence
of cardiac disease in the pregnant women was estimated to be 0.5%, of which mitral
valve disease was more common than aortic (94.5% vs. 5.5%), and MVP was more common
(39.2%) than MR (19.9%), mitral stenosis (16.9%), or combined valvular disorders
(24%<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup>. As reported by
Nanna &#x00026; Stergiopoulos<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup>, MVP
(myxomatous changes) was a major etiology of valvular heart disease in women of
childbearing age. Gelson et al.<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup> reported that MVP is the most common cardiac disorder in the
pregnant population, accounting for 12-17% of women of childbearing age. Women with
MVP in the absence of other cardiovascular disorders may tolerate pregnancy well and
do not develop remarkable cardiac complications. Although rare, more serious
complications of MVP, such as arrhythmia, infective endocarditis and cerebral
ischemic events, have been reported during pregnancy<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup>. Debates still remain in the management of MVP in
the pregnant patients. This article aimed to delve deeper into this topic.</p></sec><sec><title>CLINICAL FEATURES</title><p>The routine use of echocardiography has greatly facilitated the identification of MVP
in young adults. Symptoms are variable, but the most frequent complaints are
dizziness, palpitation and faintness<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup>. Disappearance of auscultatory findings, midsystolic click and
late systolic murmur of MR may pose a special problem in diagnosis of MVP during
pregnancy<sup>[<xref rid="r12" ref-type="bibr">12</xref>]</sup>. Perhaps
these changes leave many cases of MVP undetected leading to false reduction in the
incidence of MVP during pregnancy<sup>[<xref rid="r13" ref-type="bibr">13</xref>]</sup>. Patients with MVP may have MR and benign ventricular
ectopics. Anatomic findings of MVP include 1) mitral annular dilation, 2) redundant
and thickened leaflets, 3) myxomatous transformation of valve substance due to
collagen dissolution or disruption and severe acid mucopolysaccharide accumulation,
and 4) absence of inflammatory changes<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup>. However, these patients may not show any deterioration
throughout pregnancy<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup>. MVP with
diffusely thickened, redundant leaflets (myxomatous change) are more prone to
deformity, degeneration and infection compared to those with only MVP without
thickened leaflets (non-myxomatous changes)<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup>. Recognizing and diagnosing MVP will explain episodes of
dyspnea, palpitation and chest pain during pregnancy. Most obstetric patients with
MVP are in the low risk group, i.e., the non-myxomatous form, and should be expected
to have excellent obstetric outcomes.</p><p>Echocardiography is of special significance for the diagnosis of MVP. The parasternal
long-axis view on transthoracic echocardiography may illustrate whether the mitral
leaflets are prolapsed into the left atrial cavity by surpassing the connecting line
between the annulus of the anterior and posterior leaflets<sup>[<xref rid="r15" ref-type="bibr">15</xref>]</sup>. Besides, obvious
balloon-like changes, leaflet thickening and elongation, annular dilation, left
atrial and left ventricular enlargement, and diminution, elongation, or rupture of
chordae tendineae could be seen on two-dimensional echocardiography. On M-mode
echocardiography, posterior displacement of mitral valve coaptation line (CD
segment) is &#x0003e; 2 mm during late systolic phase, and &#x0003e; 3 mm during pansystolic
phase. Meanwhile, one or two leaflets may show hammock-like changes<sup>[<xref rid="r15" ref-type="bibr">15</xref>]</sup>. In patients with prolapse of the
anterior mitral leaflet, the mitral regurgitant flow could be seen along the
posterior wall of the left atrium (<xref ref-type="fig" rid="f1">Figure 1</xref>);
while in those with prolapse of the posterior mitral leaflet, the mitral regurgitant
flow could be seen along the anterior wall of the left atrium<sup>[<xref rid="r16" ref-type="bibr">16</xref>]</sup>.</p><p><fig id="f1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Transthoracic echocardiography of mitral valve prolapse. (A) Prolapse of
the anterior mitral leaflet with movement of the coaptation behind the
annular plane (arrow); (B) Mitral insufficiency with a regurgitant flow
along the posterior wall of the left atrium (arrow).</p><p>LA=left atrium; LV=left ventricle</p></caption><graphic xlink:href="rbccv-31-02-0158-g01"/></fig></p></sec><sec><title>MATERNAL PROGNOSIS</title><p>The severity of prolapse depends on factors that reduce ventricular volume, which is
in an inverse proportion to the extent of MVP. The smaller the ventricular volume,
the greater the prolapse<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup>.
Although the course and the prognosis of MVP are often benign, it may be complicated
infrequently by progressive MR, ruptured chordae tendineae, infective endocarditis,
transient ischemic attacks, malignant arrhythmias, or sudden death<sup>[<xref rid="r17" ref-type="bibr">17</xref>]</sup>. There have also been a few case
reports regarding more serious complications associated with MVP during pregnancy,
such as cerebrovascular accident<sup>[<xref rid="r18" ref-type="bibr">18</xref>]</sup>, thromboembolic ischemia<sup>[<xref rid="r19" ref-type="bibr">19</xref>]</sup> and infective endocarditis<sup>[<xref rid="r20" ref-type="bibr">20</xref>]</sup>. Sugrue et al.<sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup> reported a case of postpartum group B
streptococcal endocarditis developed following uncomplicated spontaneous vaginal
delivery. Echocardiography showed moderate to severe MR, and vegetation on the
atrial surfaces of both leaflets<sup>[<xref rid="r20" ref-type="bibr">20</xref>]</sup>. More definitive recommendations regarding prophylaxis for MVP
and uncomplicated vaginal delivery await further study<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup>. Sugrue et al.<sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup> proposed that routine peripartum antibiotic prophylaxis
was not indicated for the prevention of infective endocarditis and prophylaxis
should only be given to a complicated delivery and for patients with MR. However,
infective endocarditis and asymptomatic puerperal bacteremia after normal vaginal
delivery are uncommon. There is evidence that antibiotic prophylaxis may increase
the risk of refractory endocarditis, and recommended prophylactic regimens carry a
considerable risk of drug toxicity.</p></sec><sec><title>FETAL OUTCOME</title><p>Several studies have examined the possible association between MVP and pregnancy
outcomes. Maternal valvular heart diseases have been associated with lower Apgar
scores, increased preterm delivery rate, intrauterine growth restriction and reduced
birth weight in the newborn<sup>[<xref rid="r22" ref-type="bibr">22</xref>]</sup>.
The risk to both the mother and the fetus might get exponentially increased with the
complexity of the valvular disorders, such as hemodynamic status, heart function
class, cyanotic manifestations and pulmonary artery hypertension<sup>[<xref rid="r23" ref-type="bibr">23</xref>]</sup>. Chia et al.<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup> investigated pregnancy outcomes in
28 patients with echocardiographic evidence of non-myxomatous MVP, all the patients
remained well during pregnancy. Tang et al.<sup>[<xref rid="r24" ref-type="bibr">24</xref>]</sup> examined 37 pregnancies in women with MVP with no cardiac
complications or maternal mortality associated with either vaginal or cesarean
delivery. Chen et al.<sup>[<xref rid="r25" ref-type="bibr">25</xref>]</sup>
conducted a large-scale study to evaluate pregnancy outcomes of 3,104 women with
MVP, and found higher rates of preterm birth and cesarean section in a multivariate
model. No association between mitral valve disorder and recurrent abortions was
noted. A possible explanation might be an increase in platelet activity in the
presence of MR<sup>[<xref rid="r26" ref-type="bibr">26</xref>]</sup>.</p><p>Patients with non-myxomatous MVP showed much better prognosis than those with
myxomatous MVP as evidenced by echocardiography<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup>. Non-myxomatous MVP presents little or no obstetric risk in
terms of pregnancy, labor and neonatal complications, with a cesarean section rate
of 14.3% and excellent neonatal outcomes<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup>. In terms of adverse pregnancy outcomes, Chen et
al.<sup>[<xref rid="r25" ref-type="bibr">25</xref>]</sup> found that mothers
with MVP were significantly more likely to have neonates with low body weight,
preterm birth and cesarean delivery, and found that the distributions of outcomes
including intrapartum complications, low Apgar scores, and congenital malformation
did not differ significantly between women with and those without MVP. Women with an
MVP were significantly at a 1.27- and 1.34-fold increased risk of having preterm
births and cesarean deliveries, respectively. The link between MVP and preterm
delivery was postulated as a result of discordant muscle traction, or lower muscle
tone<sup>[<xref rid="r25" ref-type="bibr">25</xref>]</sup>. The discordant
muscle traction, especially during pregnancy, might synchronously affect both
cardiac papillary and uterine cervical muscles<sup>[<xref rid="r25" ref-type="bibr">25</xref>]</sup>. The characterized collagen dissolution of the mitral
valve with secondary myxomatous transformation supported this hypothesis<sup>[<xref rid="r13" ref-type="bibr">13</xref>]</sup>.</p></sec><sec><title>TREATMENT</title><p>The pregnancy-related cardiovascular changes often aggravate the clinical
manifestations in the pregnant patients with valvular diseases. Female patients with
severe valvular disorders should avoid pregnancy, due to the concern of high risks
of maternal and fetal morbidity and mortality rates. In the patients with mild
valvular lesions, pregnancy can be preceded under close monitoring by a
sophisticated multidisciplinary team including the obstetrician, cardiologist and
obstetric anesthesiologist<sup>[<xref rid="r27" ref-type="bibr">27</xref>]</sup>.
Due to a drop in systemic vascular resistance and a decrease of left ventricular
afterload, MR is often well-tolerated during pregnancy<sup>[<xref rid="r28" ref-type="bibr">28</xref>]</sup>. The pregnant patients with mild MR, normal left
ventricular function without clinical symptoms are at low risks of
pregnancy-associated complications. Asymptomatic women with non-myxomatous MVP with
trivial or no MR probably do not require routine antibiotic prophylaxis and have
excellent prognosis<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup>; while
symptomatic heart failure can be treated with nitrates, hydralazine, diuretics and
digoxin<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup>. Patients with
arrhythmias, chest pain and palpitations often require &#x003b2;-blockers, such as
propranolol<sup>[<xref rid="r13" ref-type="bibr">13</xref>]</sup>. If the
pregnant patients progress into left ventricular dysfunction, they may develop
pulmonary congestion, for which a restricted activity, a low-sodium intake and
medical treatment with diuretics, &#x003b2;-blockers and vasodilators, are necessary.
Though propranolol is the drug of choice in this condition, unfortunately, it might
be of fetal hazards by readily crossing the placenta, and its safety during first
trimester has been suspected. It causes an increase in uterine tone, which can
potentially lead to a small infarcted placenta and a low-birth-weight infant through
the &#x003b2;-blocking action on the uterus. Propranolol works directly as a
&#x003b2;-blocker and also has a quinidine-like action. The use of propranolol at or
close to the time of delivery can cause adverse neonatal effects, such as apnea,
respiratory distress, bradycardia and hypoglycemia<sup>[<xref rid="r29" ref-type="bibr">29</xref>]</sup>. Growth retardation was noted in babies receiving
atenolol in the first trimester, &#x003b2;-blockers should therefore be avoided in
the first trimester and cardioselective &#x003b2;<sub>1</sub>-blockers, such as
atenolol, are the preferred agents for the second and third trimesters, as they may
interfere less with &#x003b2;<sub>2</sub>-mediated peripheral vasodilatation and
uterine relaxation<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup><sub>.</sub>
Moreover, vasodilators should be cautiously used in the pregnant patients,
concerning the potential uteroplacental hypoperfusion<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup>. If vasodilators are required for symptomatic
relief, hydralazine and nitrates can be used, instead<sup>[<xref rid="r30" ref-type="bibr">30</xref>]</sup>. Angiotension-converting enzyme inhibitors are
contraindicated in pregnancy and should be avoided<sup>[<xref rid="r30" ref-type="bibr">30</xref>]</sup>.</p><p>The female patients with severe MR and significant symptoms, or left ventricular
functional impairment, warrant a valvular operation before a planned pregnancy,
favorably with a valve repair procedure. Due to the fact that MVP is often a result
of elongated or ruptured chordae tendineae, correction of MVP can be resorted to
chordae replacement with mold pre built bovine pericardial chords (Braile-Gregori
prosthesis) in addition to the rigid prosthetic semicircular ring (Gregori-Braile
ring) for correction of mitral annulus dilation, in the replace of the widely
accepted valve replacement<sup>[<xref rid="r31" ref-type="bibr">31</xref>]</sup>.
The management strategies of MR due to MVP in pregnant patients were summarized in
<xref ref-type="fig" rid="f2">Figure 2</xref>. Surgical treatment of severe MR
should be avoided concerning the materno-fetal risks during pregnancy except for the
life-threatening infective endocarditis. In such cases, vaginal delivery is the
preferred mode of delivery<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup>.</p><p><fig id="f2" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>The management strategies of mitral regurgitation due to mitral valve
prolapse in pregnant patients<sup>[<xref rid="r9" ref-type="bibr">9</xref>,<xref rid="r10" ref-type="bibr">10</xref>,<xref rid="r30" ref-type="bibr">30</xref>]</sup>.</p><p>IE=infective endocarditis; LV=left ventricle; MR=mitral valve
regurgitation; MVP=mitral valve prolapse</p></caption><graphic xlink:href="rbccv-31-02-0158-g02"/></fig></p></sec><sec><title>ANESTHESIA</title><p>Regional anesthesia is usually avoided because of the sympathetic denervation
resulting in increased venous capacity and decreased peripheral resistance. This
leads to a reduction of ventricular volume, which may increase the degree of
prolapse. However, the safe use of epidural anesthesia in a patient with MVP has
been reported<sup>[<xref rid="r32" ref-type="bibr">32</xref>]</sup>. It is quite
possible that the majorities remain undiagnosed during pregnancy and undergo
regional anesthesia without any untoward hemodynamic side effects<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup>. Current American Heart Association
guidelines stipulate that the presence of a murmur or echocardiographically
demonstrated MR in patients with MVP constitutes a moderate risk of endocarditis
with invasive procedures<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup>.</p></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>Women with MVP in the absence of other cardiovascular problems may tolerate pregnancy
well. In the pregnant patients with MVP progressing into major complications,
surgical interventions should be considered. Medicinal treatment in such patients
with &#x003b2;-blockers should be a concern for the fetal safety. In the patients
with severe MR and left ventricular fuctional impairment or New York Heart
Association function class III or IV, delivery should be with the aid of carefully
titrated epidural anesthesia and invasive hemodynamic monitoring.</p><table-wrap id="t2" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="10%" span="1"/><col width="90%" span="1"/></colgroup><thead><tr><th colspan="2" align="left" rowspan="1">Authors' roles &#x00026; responsibilities</th></tr></thead><tbody><tr><td valign="top" rowspan="1" colspan="1">SMY</td><td rowspan="1" colspan="1">Study conception and design; analysis and/or interpretation of data;
manuscript writing; final approval of the manuscript</td></tr><tr><td valign="top" rowspan="1" colspan="1">SLY</td><td rowspan="1" colspan="1">Analysis and/or interpretation of data; final approval of the
manuscript</td></tr></tbody></table></table-wrap></sec></body><back><fn-group><fn fn-type="other"><p>This study was carried out at The First Hospital of Putian, Teaching Hospital,
Fujian Medical University, Putian, Fujian Province, People's Republic of
China.</p></fn><fn fn-type="supported-by"><p>No financial support.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayek</surname><given-names>E</given-names></name><name><surname>Gring</surname><given-names>CN</given-names></name><name><surname>Griffin</surname><given-names>BP</given-names></name></person-group><article-title>Mitral valve prolapse</article-title><source>Lancet</source><year>2005</year><volume>365</volume><issue>9458</issue><fpage>507</fpage><lpage>518</lpage><pub-id pub-id-type="pmid">15705461</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dill-Russell</surname><given-names>P</given-names></name><name><surname>Jones</surname><given-names>LS</given-names></name></person-group><article-title>Anaesthesia for caesarean section in a patient with Ehlers-Danlos
syndrome and mitral valve prolapse</article-title><source>Int J Obstet Anesth</source><year>2001</year><volume>10</volume><issue>3</issue><fpage>192</fpage><lpage>197</lpage><pub-id pub-id-type="pmid">15321609</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilcken</surname><given-names>DE</given-names></name><name><surname>Hickey</surname><given-names>AJ</given-names></name></person-group><article-title>Lifetime risk for patients with mitral valve prolapse of
developing severe valve regurgitation requiring surgery</article-title><source>Circulation</source><year>1988</year><volume>78</volume><issue>1</issue><fpage>10</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">3383395</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chia</surname><given-names>YT</given-names></name><name><surname>Yeoh</surname><given-names>SC</given-names></name><name><surname>Lim</surname><given-names>MC</given-names></name><name><surname>Viegas</surname><given-names>OA</given-names></name><name><surname>Ratnam</surname><given-names>SS</given-names></name></person-group><article-title>Pregnancy outcome and mitral valve prolapse</article-title><source>Asia Oceania J Obstet Gynaecol</source><year>1994</year><volume>20</volume><issue>4</issue><fpage>383</fpage><lpage>388</lpage><pub-id pub-id-type="pmid">7832670</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devereux</surname><given-names>RB</given-names></name><name><surname>Brown</surname><given-names>WT</given-names></name><name><surname>Kramer-Fox</surname><given-names>R</given-names></name><name><surname>Sachs</surname><given-names>I</given-names></name></person-group><article-title>Inheritance of mitral valve prolapse: effect of age and sex on
gene expression</article-title><source>Ann Intern Med</source><year>1982</year><volume>97</volume><issue>6</issue><fpage>826</fpage><lpage>832</lpage><pub-id pub-id-type="pmid">7149490</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishimura</surname><given-names>RA</given-names></name><name><surname>McGoon</surname><given-names>MD</given-names></name><name><surname>Shub</surname><given-names>C</given-names></name><name><surname>Miller</surname><given-names>FA Jr</given-names></name><name><surname>Ilstrup</surname><given-names>DM</given-names></name><name><surname>Tajik</surname><given-names>AJ</given-names></name></person-group><article-title>Echocardiographically documented mitral-valve prolapse. Long-term
follow-up of 237 patients</article-title><source>N Engl J Med</source><year>1985</year><volume>313</volume><issue>21</issue><fpage>1305</fpage><lpage>1309</lpage><pub-id pub-id-type="pmid">4058522</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>SM</given-names></name></person-group><article-title>Cardiac myxoma in pregnancy: a comprehensive
review</article-title><source>Rev Bras Cir Cardiovasc</source><year>2015</year><volume>30</volume><issue>3</issue><fpage>386</fpage><lpage>394</lpage><pub-id pub-id-type="pmid">26313731</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faiz</surname><given-names>SA</given-names></name><name><surname>Al-Meshari</surname><given-names>AA</given-names></name><name><surname>Sporrong</surname><given-names>BG</given-names></name></person-group><article-title>Pregnancy and valvular heart disease</article-title><source>Saudi Med J</source><year>2003</year><volume>24</volume><issue>10</issue><fpage>1098</fpage><lpage>1101</lpage><pub-id pub-id-type="pmid">14578976</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nanna</surname><given-names>M</given-names></name><name><surname>Stergiopoulos</surname><given-names>K</given-names></name></person-group><article-title>Pregnancy complicated by valvular heart disease: an
update</article-title><source>J Am Heart Assoc</source><year>2014</year><volume>3</volume><issue>3</issue><elocation-id/></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gelson</surname><given-names>E</given-names></name><name><surname>Johnson</surname><given-names>M</given-names></name><name><surname>Gatzoulis</surname><given-names>M</given-names></name><name><surname>Abselm</surname><given-names>U</given-names></name></person-group><article-title>Cardiac disease in pregnancy. Part 2: acquired heart
disease</article-title><source>Obstet Gynaecol (TOG)</source><year>2007</year><volume>9</volume><issue>2</issue><fpage>83</fpage><lpage>87</lpage></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kucharczyk-Petryka</surname><given-names>E</given-names></name><name><surname>Mamcarz</surname><given-names>A</given-names></name><name><surname>Braksator</surname><given-names>W</given-names></name><name><surname>Sawicki</surname><given-names>W</given-names></name><name><surname>D&#x00142;uzniewski</surname><given-names>M</given-names></name></person-group><article-title>Mitral valve prolapse at pregnancy: is it a real clinical
problem?</article-title><source>Pol Arch Med Wewn</source><year>2005</year><volume>114</volume><issue>5</issue><fpage>1084</fpage><lpage>1088</lpage><pub-id pub-id-type="pmid">16789507</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hass</surname><given-names>JM</given-names></name></person-group><article-title>The effect of pregnancy on the midsystolic click and murmur of
the prolapsing posterior leaflet of the mitral valve</article-title><source>Am Heart J</source><year>1976</year><volume>92</volume><issue>3</issue><fpage>407</fpage><lpage>408</lpage><pub-id pub-id-type="pmid">949036</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jana</surname><given-names>N</given-names></name><name><surname>Vasishta</surname><given-names>K</given-names></name><name><surname>Khunnu</surname><given-names>B</given-names></name><name><surname>Dhall</surname><given-names>GI</given-names></name><name><surname>Grover</surname><given-names>A</given-names></name></person-group><article-title>Pregnancy in association with mitral valve
prolapse</article-title><source>Asia Oceania J Obstet Gynaecol</source><year>1993</year><volume>19</volume><issue>1</issue><fpage>61</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">8489469</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hickey</surname><given-names>AJ</given-names></name><name><surname>MacMahon</surname><given-names>SW</given-names></name><name><surname>Wilcken</surname><given-names>DE</given-names></name></person-group><article-title>Mitral valve prolapse and bacterial endocarditis: when is
antibiotic prophylaxis necessary?</article-title><source>Am Heart J</source><year>1985</year><volume>109</volume><issue>3</issue><issue-part>Pt 1</issue-part><fpage>431</fpage><lpage>435</lpage><pub-id pub-id-type="pmid">3976467</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>CQ</given-names></name><name><surname>Liu</surname><given-names>YN</given-names></name><name><surname>Xu</surname><given-names>JJ</given-names></name><name><surname>Wang</surname><given-names>YM</given-names></name><name><surname>Huang</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>YJ</given-names></name><etal/></person-group><article-title>Transthoracic echocardiographic evaluation of the location of
mitral valvular prolapse</article-title><source>Chin J Ultras Med</source><year>2009</year><volume>25</volume><issue>1</issue><fpage>33</fpage><lpage>35</lpage></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ueki</surname><given-names>Y</given-names></name><name><surname>Izawa</surname><given-names>A</given-names></name><name><surname>Ebisawa</surname><given-names>S</given-names></name><name><surname>Motoki</surname><given-names>H</given-names></name><name><surname>Miyashita</surname><given-names>Y</given-names></name><name><surname>Tomita</surname><given-names>T</given-names></name><etal/></person-group><article-title>Infective endocarditis associated with mitral valve prolapse in a
patient with Klinefelter syndrome</article-title><source>Intern Med</source><year>2014</year><volume>53</volume><issue>9</issue><fpage>969</fpage><lpage>972</lpage><pub-id pub-id-type="pmid">24785888</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeresaty</surname><given-names>RM</given-names></name></person-group><article-title>Mitral valve prolapse. An update</article-title><source>JAMA</source><year>1985</year><volume>254</volume><issue>6</issue><fpage>793</fpage><lpage>795</lpage><pub-id pub-id-type="pmid">4009913</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anzalone</surname><given-names>N</given-names></name><name><surname>Landi</surname><given-names>G</given-names></name></person-group><article-title>Lacunar infarction in a puerpera with mitral valve
prolapse</article-title><source>Ital J Neurol Sci</source><year>1988</year><volume>9</volume><issue>5</issue><fpage>515</fpage><lpage>517</lpage><pub-id pub-id-type="pmid">3215753</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Artal</surname><given-names>R</given-names></name><name><surname>Greenspoon</surname><given-names>JS</given-names></name><name><surname>Rutherford</surname><given-names>S</given-names></name></person-group><article-title>Transient ischemic attack: a complication of mitral valve
prolapse in pregnancy</article-title><source>Obstet Gynecol</source><year>1988</year><volume>71</volume><issue>6</issue><issue-part>2</issue-part><fpage>1028</fpage><lpage>1030</lpage><pub-id pub-id-type="pmid">3374915</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strasberg</surname><given-names>GD</given-names></name></person-group><article-title>Postpartum group B streptococcal endocarditis associated with
mitral valve prolapse</article-title><source>Obstet Gynecol</source><year>1987</year><volume>70</volume><issue>3</issue><issue-part>Pt 2</issue-part><fpage>485</fpage><lpage>487</lpage><pub-id pub-id-type="pmid">3306506</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugrue</surname><given-names>D</given-names></name><name><surname>Blake</surname><given-names>S</given-names></name><name><surname>Troy</surname><given-names>P</given-names></name><name><surname>MacDonald</surname><given-names>D</given-names></name></person-group><article-title>Antibiotic prophylaxis against infective endocarditis after
normal delivery: is it necessary?</article-title><source>Br Heart J</source><year>1980</year><volume>44</volume><issue>5</issue><fpage>499</fpage><lpage>502</lpage><pub-id pub-id-type="pmid">7437187</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hameed</surname><given-names>A</given-names></name><name><surname>Karaalp</surname><given-names>IS</given-names></name><name><surname>Tummala</surname><given-names>PP</given-names></name><name><surname>Wani</surname><given-names>OR</given-names></name><name><surname>Canetti</surname><given-names>M</given-names></name><name><surname>Akhter</surname><given-names>MW</given-names></name><etal/></person-group><article-title>The effect of valvular heart disease on maternal and fetal
outcome of pregnancy</article-title><source>J Am Coll Cardiol</source><year>2001</year><volume>37</volume><issue>3</issue><fpage>893</fpage><lpage>899</lpage><pub-id pub-id-type="pmid">11693767</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elliott</surname><given-names>C</given-names></name><name><surname>Sliwa</surname><given-names>K</given-names></name><name><surname>Burton</surname><given-names>R</given-names></name></person-group><article-title>Pregnancy and cardiac disease</article-title><source>S Afr Med J</source><year>2014</year><volume>104</volume><issue>9</issue><fpage>641</fpage><lpage>641</lpage><pub-id pub-id-type="pmid">26307787</pub-id></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>LC</given-names></name><name><surname>Chan</surname><given-names>SY</given-names></name><name><surname>Wong</surname><given-names>VC</given-names></name><name><surname>Ma</surname><given-names>HK</given-names></name></person-group><article-title>Pregnancy in patients with mitral valve prolapse</article-title><source>Int J Gynaecol Obstet</source><year>1985</year><volume>23</volume><issue>3</issue><fpage>217</fpage><lpage>221</lpage><pub-id pub-id-type="pmid">2865185</pub-id></element-citation></ref><ref id="r25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>CH</given-names></name><name><surname>Huang</surname><given-names>MC</given-names></name><name><surname>Liu</surname><given-names>HC</given-names></name><name><surname>Huang</surname><given-names>CJ</given-names></name><name><surname>Lin</surname><given-names>HC</given-names></name><name><surname>Kou</surname><given-names>YR</given-names></name></person-group><article-title>Increased risk of preterm birth among women with mitral valve
prolapse: a nationwide, population-based study</article-title><source>Ann Epidemiol</source><year>2011</year><volume>21</volume><issue>6</issue><fpage>391</fpage><lpage>398</lpage><pub-id pub-id-type="pmid">21435902</pub-id></element-citation></ref><ref id="r26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martini</surname><given-names>F</given-names></name><name><surname>Zuppiroli</surname><given-names>A</given-names></name><name><surname>Gori</surname><given-names>A</given-names></name><name><surname>Chiarantini</surname><given-names>E</given-names></name><name><surname>Fedi</surname><given-names>S</given-names></name><name><surname>Prisco</surname><given-names>D</given-names></name><etal/></person-group><article-title>Platelet and blood clotting activation in patients with mitral
valve prolapse</article-title><source>Thromb Res</source><year>1996</year><volume>83</volume><issue>4</issue><fpage>299</fpage><lpage>306</lpage><pub-id pub-id-type="pmid">8870174</pub-id></element-citation></ref><ref id="r27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sen</surname><given-names>M</given-names></name><name><surname>Bhattacharyya</surname><given-names>P</given-names></name><name><surname>Chowdhury</surname><given-names>N</given-names></name></person-group><article-title>Pregnancy with heart disease: fetomaternal
outcome</article-title><source>J Evol Med Dental Sci</source><year>2014</year><volume>3</volume><issue>5</issue><fpage>1178</fpage><lpage>1183</lpage></element-citation></ref><ref id="r28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roeder</surname><given-names>HA</given-names></name><name><surname>Kuller</surname><given-names>JA</given-names></name><name><surname>Barker</surname><given-names>PC</given-names></name><name><surname>James</surname><given-names>AH</given-names></name></person-group><article-title>Maternal valvular heart disease in pregnancy</article-title><source>Obstet Gynecol Surv</source><year>2011</year><volume>66</volume><issue>9</issue><fpage>561</fpage><lpage>571</lpage><pub-id pub-id-type="pmid">22088233</pub-id></element-citation></ref><ref id="r29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Little</surname><given-names>BB</given-names></name><name><surname>Gilstrap 3rd</surname><given-names>LC</given-names></name></person-group><article-title>Cardiovascular drugs during pregnancy</article-title><source>Clin Obstet Gynecol</source><year>1989</year><volume>32</volume><issue>1</issue><fpage>13</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">2661075</pub-id></element-citation></ref><ref id="r30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsiaras</surname><given-names>S</given-names></name><name><surname>Poppas</surname><given-names>A</given-names></name></person-group><article-title>Mitral valve disease in pregnancy: outcomes and
management</article-title><source>Obstet Med</source><year>2009</year><volume>2</volume><issue>1</issue><fpage>6</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">27582798</pub-id></element-citation></ref><ref id="r31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gregori Junior</surname><given-names>F</given-names></name></person-group><article-title>Conservative surgical management of mitral insufficiency: an
alternative approach</article-title><source>Rev Bras Cir Cardiovasc</source><year>2012</year><volume>27</volume><issue>2</issue><fpage>312</fpage><lpage>317</lpage><pub-id pub-id-type="pmid">22996984</pub-id></element-citation></ref><ref id="r32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruiz-Castro</surname><given-names>M</given-names></name><name><surname>Sanz</surname><given-names>M</given-names></name><name><surname>Vidal</surname><given-names>A</given-names></name><name><surname>Infante</surname><given-names>B</given-names></name><name><surname>Palma</surname><given-names>MA</given-names></name></person-group><article-title>Anesthesia for cesarean section in patients with mitral valve
prolapse</article-title><source>Rev Esp Anestesiol Reanim</source><year>1996</year><volume>43</volume><issue>8</issue><fpage>291</fpage><lpage>293</lpage><pub-id pub-id-type="pmid">9011900</pub-id></element-citation></ref></ref-list></back></article>